All In Biotech

Drug Trial Radar · NCT06545331

Study of XB010 in Subjects With Solid Tumors

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

396

Planned (sponsor's estimate)

Start

Aug 6, 2024

Primary completion

Nov 23, 2026

Study completion Oct 20, 2027

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Conditions

  • Locally Advanced or Metastatic Solid Tumors
  • Esophageal Squamous Cell Cancer
  • Head and Neck Squamous Cell Cancer
  • NSCLC (Non-small Cell Lung Cancer)
  • Hormone-receptor-positive Breast Cancer
  • Triple Negative Breast Cancer (TNBC)

Interventions

  • XB010Drug

    IV administration of XB010

  • PembrolizumabDrug

    IV administration of Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010Time frame: 18 months
  2. Dose-Escalation Stage: Safety of XB010Time frame: 18 months
  3. Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability]Time frame: 18 months
  4. Dose-Escalation Stage: Dose intensity of XB010 [Tolerability]Time frame: 18 months
  5. Cohort-Expansion Stage: Preliminary antitumor activity of XB010Time frame: 24 months

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • UCLA Department of Medicine - Hematology/Oncology

    Los Angeles, California · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Completed

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Montefiore Medical Center - Montefiore Medical Park

    The Bronx, New York · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Completed

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • NEXT Austin

    Austin, Texas · Recruiting

  • Baylor University Medical Center

    Dallas, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Inova Schar Cancer

    Fairfax, Virginia · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom · Recruiting

  • Sarah Cannon Research Institute London

    London, United Kingdom · Recruiting

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.